Sources: Sanofi’s Brandicourt looks at spinoff of animal health, selling supplement biz

Eric Palmer New Sanofi CEO Olivier Brandicourt has promised to unveil his 5-year strategic plan for the French drugmaker and he appears to be homing in on what to keep and ...

Fierce’s coverage of the Martin Shkreli saga

Alok Saboo Martin Shkreli's controversial Turing Pharmaceuticals made global headlines this week after the startup chose to jack up the price of a decades-old drug to boost revenue, ...

Novo Nordisk strikes deal with Iran government to produce insulin pens in the country

Eric Palmer Novo Nordisk will step up its operations in Iran, saying today it will build a €70 million ($ 78.1 million) plant to produce its FlexPen prefilled devices to better ...

The Shkreli scandal leaves a big mess for biotech to clean up

John Carroll The industry now has to deal with the fact that drug pricing has taken center stage in presidential politics. And the story of Daraprim, Martin Shkreli and price gouging ...

Deerfield leads a $75M round for Akari

John Carroll FierceBiotech News

HIV activists join Janssen’s story-focused Prezcobix effort

Beth Snyder Bulik Some heavy-hitting HIV activists have signed on to Janssen's ongoing "Wisdom" campaign, headlining a share-your-story campaign for people living with ...

Perrigo CEO has slammed Mylan for months–but he owns its shares

Carly Helfand Perrigo CEO Joseph Papa has cautioned investors against taking up an offer from hostile suitor Mylan. But Papa is already a Mylan shareholder himself. FiercePharma News

COMMENTARY: Why would Martin Shkreli hike an old drug price by 5000%? Only a ‘moron’ would ask

John Carroll FierceBiotech News

Novartis CEO stands by emerging markets even as China economy continues to weaken

Eric Palmer China's economy is a mess and other emerging markets are flailing about as well. So what is pharma CEO to do if they have bet big on growth in the EM realm? Keep on ...

Nabriva pulls off a down-sized IPO, raising $92M for antibiotic R&D

Damian Garde Antibiotics biotech Nabriva Therapeutics executed a $ 92.3 million IPO, pricing well below its projected range but scraping together the funds it needs to start a Phase ...

With $1B in VC cash, Intarcia is happy to stay out of the IPO scrum

Damian Garde Intarcia Therapeutics is rolling toward an FDA application with its long-acting diabetes treatment, but despite the ready availability of IPO cash for drug developers, ...

Intas CEO expects to break into U.S. biosimilar market yet this year

Eric Palmer The CEO of Intas Pharmaceuticals expects his company to get FDA approval this year for its biosimilar of Amgen's Neulasta, a drug it developed with Canada's Apotex. FiercePharma ...
Page 1 of 41234
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS